Kilitch Drugs Sets Rights Issue Price at Rs 357, Eyes Expansion Boost

Kilitch Drugs (India) Ltd has set the issue price of its forthcoming rights issue at Rs 357 a share, according to its July 2, 2025 board meeting result. The action is part of a Rs 50 crore capital raise to confirm strategic growth.

Key Highlights:

Rights Issue Details:

Existing shareholders will be given the equity shares of face value of Rs 10.

Date for eligibility record will be notified later on.

Purpose of Fundraising:

Capital will finance a Greenfield manufacturing venture in Pen, Maharashtra.

Additional funds will cover general corporate expenses and rights issue-related costs.

Market Snapshot:

Kilitch Drugs closed at Rs 449.70, below its 52-week high price of Rs 499.

Market capitalisation of the company is Rs 723.22 crore and its P/E is 27.09.

Sources: HDFC Sky, Economic Times, Moneycontrol